Biogen (BIIB) PT Lowered to $200 at Barclays
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $216.12 +3.04%
Rating Summary:
26 Buy, 17 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 2
Rating Summary:
26 Buy, 17 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 2
Join SI Premium – FREE
Barclays analyst Carter Gould lowered the price target on Biogen (NASDAQ: BIIB) to $200.00 (from $215.00) while maintaining a Equalweight rating.
You May Also Be Interested In
- Biogen expects $164M R&D charge to hit Q2 2026 earnings
- Wipro Ltd. (WPRO:IN) (WIT) PT Lowered to INR170 at BNP Paribas Exane
- HCL Technologies (HCLT:IN) PT Lowered to INR1,110 at BNP Paribas Exane
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
